In a year where ADC deals have showed no signs of slowing, Solve has become the latest biotech to unlock an extra slice of capital.
Pharmaceutical Technology on MSN
MSD bets big on flu antivirals with $9.2bn buyout of Cidara
MSD has now agreed two deals around the $10bn mark in 2025 as it looks to shore up its pipeline with Keytruda’s looming ...
The LDL-C reductions seen with enlicitide in both studies are in the same ballpark as those seen with injectable ...
MSD has announced a takeover deal for Cidara Therapeutics, an infectious disease specialist currently focused on developing a ...
MSD (known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada) is collaborating with hospitals in Hanoi and Ho Chi Minh City to hold a series of scientific seminars titled “Updates ...
MSD has announced positive results from its phase 3 CORALreef Lipids trial, showing that enlicitide decanoate, an investigational oral PCSK9 inhibitor, significantly reduced low-density lipoprotein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback